LOTUSEYELotus Eye Hospital and Institute Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 26.2% YoY
- • Debt/Equity: 0.26
- • Promoter holding: 70.3%
- • RSI: 52
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
- • Pullback to 21-EMA signal (setup quality 64%)
Bull case
- • Revenue growth: 26.2% YoY
- • Debt/Equity: 0.26
- • Promoter holding: 70.3%
- • RSI: 52
Bear case
- • ROE: 0.1%
- • ROCE: -0.5%
- • Price vs SMA50: below
- • Price vs SMA200: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • ROE: 0.1%
- • ROCE: -0.5%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.08). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.